ProfileGDS5678 / 1424075_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 81% 80% 84% 83% 79% 82% 81% 80% 81% 82% 82% 81% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.8188282
GSM967853U87-EV human glioblastoma xenograft - Control 25.8762881
GSM967854U87-EV human glioblastoma xenograft - Control 35.7050680
GSM967855U87-EV human glioblastoma xenograft - Control 46.4635584
GSM967856U87-EV human glioblastoma xenograft - Control 56.1717683
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.302579
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.7931582
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.8364981
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.6577680
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.896681
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.9012982
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.9408482
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.8295181
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.8562482